Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC

Clinical trial NCT06861894 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06861894
Sponsor: Zhigang Li
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Esophageal Squamous Cell Carcinoma

Start date: 2025-07-01
Primary completion: 2027-03-01
Enrollment: 164

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.